We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.85 | -1.11% | 75.56 | 75.39 | 76.56 | 76.41 | 75.75 | 76.26 | 10,038,808 | 01:00:00 |
From May 2019 to May 2024
By Anthony O. Goriainoff
AstraZeneca PLC said Wednesday that Enhertu has been granted conditional approval by the EU as a monotherapy for the treatment for breast cancer.
The U.K. pharmaceuticals giant said the approval was based on positive results from the single-arm DESTINY-Breast01 Phase II trial. The company said Enhertu showed "clinically meaningful and durable antitumor activity in patients with HER2-positive metastatic breast cancer who had received two or more prior anti-HER2-based regimens."
The company has developed Enhertu--a HER2-directed antibody drug conjugate-- in collaboration with Japan's Sankyo Co. The company said that following EU approval the Japanese company is due a $75-million payment from AstraZeneca as a milestone payment for HER2.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
January 20, 2021 02:33 ET (07:33 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
